Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

Axonics Modulation Technologies, Inc.. (7/6/17). "Presss Release: Axonics Announces $20.5 Million Second Closing of Its Series C Financing". Irvine, CA.

Organisations Organisation Axonics Modulation Technologies Inc.
  Organisation 2 Gilde Healthcare Partners B.V.
  Group Gilde Investment (Group)
Products Product r-SNM™ system (rechargeable Sacral Neuromodulation system)
  Product 2 venture capital
Index terms Index term Axonics–SEVERAL: investment, 201707 financing round Series C $20.5m 2nd closing bringing total Series C to $35m
  Index term 2 Axonics–Gilde Investment: investment, 201707 financing round Series C $20.5m 2nd closing incl new investor Gilde Healthcare
     


Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $20.5 million second closing of its Series C financing, bringing the total amount of capital raised for its Series C to $35 million.

The second closing of the Series C round included two new investors, Gilde Healthcare, which has offices in Boston and Utrecht, Netherlands, and CICA, Inc. based in La Jolla, California. Existing investor, Boston-based Cormorant Asset Management also participated in both closings as did a select group of private individuals.

Geoff Pardo, Partner at Gilde Healthcare, joined the Axonics board of directors. Pardo has significant experience in the medical device industry as an operator and venture investor.

Pardo commented, “Gilde believes that the SNM market will grow to over $1 billion in revenue in the next few years and with only one player in the market today, we are confident that Axonics, given the quality of its management team and its miniaturized implantable rechargeable system, is poised to take a measurable portion of that market following FDA approval.”

Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S. FDA approval and prepare Axonics to access markets around the world. The U.S. pivotal study is anticipated to begin in late 2017 in select medical centers in North America and Europe. During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada.

“On behalf of all the stakeholders in Axonics, we extend a warm welcome to our new world-class investors and Mr. Pardo as a new board member. The fact that this financing was oversubscribed is testament to the quality of work that the Company has done to create an innovative and highly competitive sacral neuromodulation system,” said Raymond W. Cohen, Chief Executive Officer of Axonics.


About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards several clinical indications. The Axonics r-SNM system includes a miniaturized rechargeable implantable stimulator qualified to function at least 15 years, a charging system optimized for reduced charge time with no heating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming. For more information, visit the Company’s website at www.axonicsmodulation.com.


Contacts

Company Contact:
Axonics Modulation Technologies, Inc.
Dan Dearen, 949-396-6322
Chief Operating & Financial Officer
ddearen@axonicsmodulation.com

or

Investor Contact:
Pure Communications, Inc.
Matt Clawson, 949-370-8500
mclawson@purecommunications.com

   
Record changed: 2017-07-13

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px